Pfizer share news, announcements and annual reports
NSE: PFIZERBSE: 500680Pharmaceuticals & BiotechnologySmall Cap
Pfizer Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1966 on BSE, Apr 1999 on NSE
Last close ₹3,638.70down ₹49.10 (1.33%)BSE ₹3,637.90
Share price at the NSE close on 2 Nov 2026. Previous close ₹3,687.80.
2 Nov: open ₹3,687.80, high ₹3,718.20, low ₹3,613.60
52-week range of traded prices to 2 Nov 2026
₹3,589.00Low, 23 Oct 2026₹5,339.00High, 13 Nov 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,646 Cr327th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.64
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.96
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.06%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 55,74259.3% delivered
Pfizer share news and announcements
658 announcements, routine notices left out, newest first. Page 6 of 14.
Apr 2020
3 Apr · News Verification
The exchange asked on 1 Apr 2020
Feb 2020
14 Feb · Management
14 Feb · Management
14 Feb · Results
3 Feb · Board meeting
Jan 2020
Dec 2019
Nov 2019
27 Nov · Related Party Transactions
12 Nov · Analysts
6 Nov · Analysts
5 Nov · Analysts
Oct 2019
26 Oct · Results
15 Oct · Board meeting
Sep 2019
16 Sep · Analysts
16 Sep · Analysts
Aug 2019
28 Aug · Analysts
19 Aug · Analysts
10 Aug · Meeting
9 Aug · Results
Jul 2019
29 Jul · Board meeting
22 Jul · Meeting
Jun 2019
26 Jun · Related Party Transactions
May 2019
29 May · Management
28 May · Business
28 May · Results
Apr 2019
Mar 2019
Jan 2019
29 Jan · Analysts
29 Jan · Analysts
24 Jan · Business
24 Jan · Results
15 Jan · Legal
Exchange has sought clarification from the Company with respect to news item captioned- " Pfizer to stop manufacturing operations in Chennai, Aurangabad units. In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company are aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is awaited.14 Jan · Board meeting
Dec 2018
Nov 2018
27 Nov · Analysts
19 Nov · Analysts